Merck invests in biotech development facility in Switzerland27 Jan 2020
€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.
Merck has announced an investment of €250 million in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies.
Driven by the growth of the Healthcare business sector R&D pipeline, this investment will help to sustainably secure capacity and high agility to deliver clinical trial material cost-effectively, contribute to accelerated development timelines of new biological entities, and address the increasing manufacturing complexity of the next generations of biotech compounds.
“This investment in the Merck Biotech Development Center reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck, at the groundbreaking ceremony for the new facility.
“Our investment in this biotech development facility in Switzerland is strongly related to the growth and progression of our Healthcare pipeline, and our confidence in its future potential,” said Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare.
Located near Merck’s current biotech commercial manufacturing site in Corsier-sur-Vevey, Switzerland, the Biotech Development Center will bridge research and manufacturing. The facility will consist of a building providing a total of 15,700 m2 of development space bringing together a cross-functional team of approximately 250 employees spread across different sites, responsible for advancing Merck’s biotech R&D pipeline by ensuring that the company's next generation of biotech therapies are available for clinical trials on time, on quality and on quantity.
Equipped with the most advanced digital solutions and highest technological standards, including continuous manufacturing and laboratory automation, the Biotech Development Center will offer a flexible-by-design infrastructure to readily adapt to emerging needs and technology evolution, as well as open workspaces enabling collaboration, creativity and innovation. Everything will be designed to comply with the highest international standards of quality, environment, health and safety. Sustainable features in the new building will include an abundance of natural light, a highly efficient energy management, as well as an architectural design integrated into the landscape following the contours of the slope and preserving biodiversity with special habitats promoting wildlife and protected flora.
The Biotech Development Center will showcase Merck’s science and technology across its three business sectors, including Life Sciences’ process solutions for clinical manufacturing and pilot plant operations, as well as Performance Materials’ eyrise dynamic liquid crystal windows as part of the highly efficient energy management of the building. The construction of the building is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022 following validation by regulatory authorities.
The Biotech Development Center adds to recent investments aiming to further increase Merck’s capacities in the R&D and manufacturing of medicines, such as the expansions of the R&D facility of Billerica, US, of the biotech manufacturing site of Aubonne, Switzerland, and of the pharma manufacturing site of Darmstadt, Germany. With the existing sites of Corsier-sur-Vevey and Aubonne and the future Biotech Development Center, Switzerland further confirms its position as Merck’s prime hub for the manufacturing and development of biotech medicines. Merck has invested more than one billion Swiss francs in Switzerland during the past 10 years, reflecting the strategic importance of the country, where it employs more than 2,400 employees across nine locations.
Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD
21 Feb 2020
Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.Read more
Catalent to manufacture first-in-class mAb targeting solid tumours
11 Feb 2020
ZM008 could have potential benefits for the treatment of prostate cancer.Read more
BD completes clinical trial for its wearable injector
11 Feb 2020
The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.Read more
New Velesco Pharma clinical manufacturing facility begins operations
5 Feb 2020
The facility will triple the company’s cGMP clinical trial manufacturing capacity.Read more
Inovio and Beijing Advaccine to advance vaccine against Coronavirus
30 Jan 2020
Agreement will facilitate clinical trial translations in China.Read more
First human trial of monoclonal antibody to prevent malaria opens
28 Jan 2020
If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.Read more
Thermo launches next-generation, compressor-free plate sealer
28 Jan 2020
Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.Read more
Grey Wolf Therapeutics secures funding for cancer therapies development
21 Jan 2020
The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.Read more
Diabetes diagnosis - now a matter of sweat and tears?
21 Jan 2020
No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.Read more
BioMarin gets go-ahead to start gene therapy clinical trials
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation